The International T-cell Lymphoma Project has shown differences in survival according to histology, with 5-year OS ranges from 90% for PCTL to 7% for hepatosplenic PTCL.1, 4 Therefore, entities with the best prognosis after conventional chemotherapy (ALK-positive ALCL and PCTL) usually have not been included in trials investigating the role of autoSCT as part of first-line therapy except that published by Corradini et al. (in which an additional analysis excluding ALK-positive ALCL was made). Here, ALK is linked to T-cell non-Hodgkin lymphoma.